D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Duopharma Biotech Bhd
Cost of Revenue Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Cost of Revenue
-myr478.9m
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-17%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Cost of Revenue
-myr158.9m
CAGR 3-Years
-12%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Cost of Revenue
-myr743.3m
CAGR 3-Years
-11%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Cost of Revenue
-myr162.4m
CAGR 3-Years
-13%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Cost of Revenue
-myr203.4m
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
K
Kotra Industries Bhd
KLSE:KOTRA
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Duopharma Biotech Bhd's Cost of Revenue?
Cost of Revenue
-478.9m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Cost of Revenue amounts to -478.9m MYR.

What is Duopharma Biotech Bhd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-17%

Over the last year, the Cost of Revenue growth was -16%. The average annual Cost of Revenue growth rates for Duopharma Biotech Bhd have been -11% over the past three years , -9% over the past five years , and -17% over the past ten years .

Back to Top